Advertisement
Original Study| Volume 22, ISSUE 9, P1877-1882.e2, September 2021

Intranasal Oxytocin Improves Lean Muscle Mass and Lowers LDL Cholesterol in Older Adults with Sarcopenic Obesity: A Pilot Randomized Controlled Trial

  • Sara E. Espinoza
    Correspondence
    Address correspondence to Sara E. Espinoza, MD, MSc, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229.
    Affiliations
    Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA

    Geriatric Research Education and Clinical Center, Audie L. Murphy VA Medical Center, San Antonio, TX, USA
    Search for articles by this author
  • Jessica L. Lee
    Affiliations
    Division of Geriatric and Palliative Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA
    Search for articles by this author
  • Chen-Pin Wang
    Affiliations
    Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA

    Geriatric Research Education and Clinical Center, Audie L. Murphy VA Medical Center, San Antonio, TX, USA

    Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, TX Center, San Antonio, TX, USA
    Search for articles by this author
  • Vinutha Ganapathy
    Affiliations
    Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA

    Geriatric Research Education and Clinical Center, Audie L. Murphy VA Medical Center, San Antonio, TX, USA
    Search for articles by this author
  • Daniel MacCarthy
    Affiliations
    Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA

    Geriatric Research Education and Clinical Center, Audie L. Murphy VA Medical Center, San Antonio, TX, USA

    Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, TX Center, San Antonio, TX, USA
    Search for articles by this author
  • Chiara Pascucci
    Affiliations
    Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX, USA
    Search for articles by this author
  • Nicolas Musi
    Affiliations
    Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA

    Geriatric Research Education and Clinical Center, Audie L. Murphy VA Medical Center, San Antonio, TX, USA
    Search for articles by this author
  • Elena Volpi
    Affiliations
    Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX, USA
    Search for articles by this author

      Abstract

      Objectives

      Obesity is associated with sarcopenia in older adults, and weight loss can lead to further muscle mass loss. Oxytocin decreases with age, and animal studies suggest that oxytocin administration has trophic effects on skeletal muscle cells and reduces adiposity. We conducted a clinical trial to examine the safety and preliminary efficacy of intranasal oxytocin for older adults with sarcopenic obesity.

      Design

      A double-blind, placebo-controlled randomized controlled trial of intranasal oxytocin (24 IU 4 times per day) for 8 weeks.

      Setting and Participants

      Twenty-one older (67.5 ± 5.4 years), obese (30–43 kg/m2), sedentary (<2 strenuous exercise per week) adults with slow gait speed (<1 m/s, proxy measure of sarcopenia) were recruited.

      Measures

      Generalized estimating equations were used to evaluate the effect of oxytocin on safety/tolerability of oxytocin administration and whole body muscle and fat mass.

      Results

      At baseline, body mass index (BMI) was 36.8 ± 3.6 kg/m2, fat mass 46.09 ± 6.99 kg, lean mass 50.98 ± 11.77 kg, fasting plasma glucose (FPG) 92.0 ± 8.9 mg/dL, hemoglobin A1c (HbA1c) 5.7% ± 0.4%, low density lipoprotein (LDL) 111.3 ± 41.5 mg/dL, high-density lipoprotein (HDL) 47.85 ± 10.96 mg/dL, and triglycerides 140.55 ± 83.50 mg/dL. Oxytocin administration was well tolerated without any significant adverse events. Oxytocin led to a significant increase of 2.25 kg in whole body lean mass compared with placebo (P < .01) with a trend toward decreasing fat mass, and a significantly reduced plasma LDL cholesterol by −19.3 mg/dL (P = .023) compared against placebo. There were no significant changes in BMI, appetite scores, glycemia, plasma HDL, triglycerides, or depressive symptoms.

      Conclusions and Implications

      This proof-of-concept study indicates that oxytocin may be useful for the treatment of sarcopenic obesity in older adults. Oxytocin administration may also provide additional cardiovascular benefits.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kane R.L.
        • Shamliyan T.
        • Talley K.
        • Pacala J.
        The association between geriatric syndromes and survival.
        J Am Geriatr Soc. 2012; 60: 896-904
        • Kallman D.A.
        • Plato C.C.
        • Tobin J.D.
        The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives.
        J Gerontol. 1990; 45: M82-M88
        • Batsis J.A.
        • Villareal D.T.
        Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies.
        Nat Rev Endocrinol. 2018; 14: 513-537
        • Batsis J.A.
        • Mackenzie T.A.
        • Barre L.K.
        • et al.
        Sarcopenia, sarcopenic obesity and mortality in older adults: Results from the National Health and Nutrition Examination Survey III.
        Eur J Clin Nutr. 2014; 68: 1001-1007
        • Frimel T.N.
        • Sinacore D.R.
        • Villareal D.T.
        Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults.
        Med Sci Sports Exerc. 2008; 40: 1213-1219
        • Blau H.M.
        • Cosgrove B.D.
        • Ho A.T.
        The central role of muscle stem cells in regenerative failure with aging.
        Nat Med. 2015; 21: 854
        • Elabd C.
        • Cousin W.
        • Upadhyayula P.
        • et al.
        Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration.
        Nat Commun. 2014; 5: 4082
        • Leng G.
        • Ludwig M.
        Intranasal oxytocin: Myths and delusions.
        Biol Psychiatry. 2016; 79: 243-250
        • Iwasaki Y.
        • Maejima Y.
        • Suyama S.
        • et al.
        Peripheral oxytocin activates vagal afferent neurons to suppress feeding in normal and leptin-resistant mice: A route for ameliorating hyperphagia and obesity.
        Am J Physiol Regul Integr Comp Physiol. 2015; 308: R360-R369
        • Lawson E.A.
        • Marengi D.A.
        • DeSanti R.L.
        • et al.
        Oxytocin reduces caloric intake in men.
        Obesity. 2015; 23: 950-956
        • Borg J.
        • Simren M.
        • Ohlsson B.
        Oxytocin reduces satiety scores without affecting the volume of nutrient intake or gastric emptying rate in healthy subjects.
        Neurogastroenterol Motil. 2011; 23: 56
        • Lawson E.A.
        • Olszewski P.K.
        • Weller A.
        • Blevins J.E.
        The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis.
        J Neuroendocrinol. 2020; 32: e12805
        • Zhang H.
        • Wu C.
        • Chen Q.
        • et al.
        Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models.
        PLoS One. 2013; 8: e61477
        • Blevins J.E.
        • Ho J.M.
        Role of oxytocin signaling in the regulation of body weight.
        Rev Endocr Metab Disord. 2013; 14: 311-329
        • Deblon N.
        • Veyrat-Durebex C.
        • Bourgoin L.
        • et al.
        Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats.
        PLoS One. 2011; 6: e25565
        • Montorio I.
        • Izal M.
        The Geriatric Depression Scale: A review of its development and utility.
        Int Psychogeriatr. 1996; 8: 103-112
        • Cruz-Jentoft A.J.
        • Baeyens J.P.
        • Bauer J.M.
        • et al.
        Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People.
        Age Ageing. 2010; 39: 412-423
        • Perez-Sousa M.A.
        • Venegas-Sanabria L.C.
        • Chavarro-Carvajal D.A.
        • et al.
        Gait speed as a mediator of the effect of sarcopenia on dependency in activities of daily living.
        J Cachexia Sarcopenia Muscle. 2019; 10: 1009-1015
        • Nasreddine Z.S.
        • Phillips N.A.
        • Bédirian V.
        • et al.
        The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment.
        J Am Geriatr Soc. 2005; 53: 695-699
        • Vilagut G.
        • Forero C.G.
        • Barbaglia G.
        • Alonso J.
        Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): A systematic review with meta-analysis.
        PLoS One. 2016; 11: e0155431
        • Guralnik J.M.
        • Simonsick E.M.
        • Ferrucci L.
        • et al.
        A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission.
        J Gerontol. 1994; 49: M85-M94
        • Podsiadlo D.
        • Richardson S.
        The timed “Up & Go”: A test of basic functional mobility for frail elderly persons.
        J Am Geriatr Soc. 1991; 39: 142-148
        • Wilson M.M.
        • Thomas D.R.
        • Rubenstein L.Z.
        • et al.
        Appetite assessment: Simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents.
        Am J Clin Nutr. 2005; 82: 1074-1081
        • Batsis J.A.
        • Mackenzie T.A.
        • Lopez-Jimenez F.
        • Bartels S.J.
        Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 1999–2004.
        Nutr Res. 2015; 35: 1031-1039
        • Hirani V.
        • Naganathan V.
        • Blyth F.
        • et al.
        Longitudinal associations between body composition, sarcopenic obesity and outcomes of frailty, disability, institutionalisation and mortality in community-dwelling older men: The Concord Health and Ageing in Men Project.
        Age Ageing. 2016; 46: 413-420
        • Lee E.S.
        • Uhm K.-O.
        • Lee Y.M.
        • et al.
        Oxytocin stimulates glucose uptake in skeletal muscle cells through the calcium–CaMKK–AMPK pathway.
        Regul Pept. 2008; 151: 71-74
        • Lawson E.A.
        The effects of oxytocin on eating behaviour and metabolism in humans.
        Nat Rev Endocrinol. 2017; 13: 700
        • Burt R.L.
        • Leake N.H.
        • Dannenburg W.N.
        Effect of synthetic oxytocin on plasma nonesterified fatty acids, triglycerides, and blood glucose.
        Obstet Gynecol. 1963; 21: 708-712
        • Olff M.
        • Frijling J.L.
        • Kubzansky L.D.
        • et al.
        The role of oxytocin in social bonding, stress regulation and mental health: An update on the moderating effects of context and interindividual differences.
        Psychoneuroendocrinology. 2013; 38: 1883-1894
        • Striepens N.
        • Kendrick K.M.
        • Maier W.
        • Hurlemann R.
        Prosocial effects of oxytocin and clinical evidence for its therapeutic potential.
        Front Neuroendocrinol. 2011; 32: 426-450
        • Lee H.-J.
        • Macbeth A.H.
        • Pagani J.H.
        • Young 3rd, W.S.
        Oxytocin: the great facilitator of life.
        Prog Neurobiol. 2009; 88: 127-151
        • Emiliano A.B.
        • Cruz T.
        • Pannoni V.
        • Fudge J.L.
        The interface of oxytocin-labeled cells and serotonin transporter-containing fibers in the primate hypothalamus: A substrate for SSRIs therapeutic effects?.
        Neuropsychopharmacology. 2007; 32: 977-988
        • Scantamburlo G.
        • Hansenne M.
        • Fuchs S.
        • et al.
        Plasma oxytocin levels and anxiety in patients with major depression.
        Psychoneuroendocrinology. 2007; 32: 407-410
        • Cochran D.M.
        • Fallon D.
        • Hill M.
        • Frazier J.A.
        The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings.
        Harv Rev Psychiatry. 2013; 21: 219-247
        • MacDonald E.
        • Dadds M.R.
        • Brennan J.L.
        • et al.
        A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.
        Psychoneuroendocrinology. 2011; 36: 1114-1126